A new treatment for chronic wounds using a stable growth factor formulation
Hyperstable FGF1-FGF2 based therapeutic formulation for wound care
['FUNDING_R15'] · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · NIH-10876032
This study is testing a new treatment that combines two special proteins to help heal stubborn wounds better, especially for people with diabetes and heart issues, making it easier for them to recover and improve their quality of life.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARKANSAS AT FAYETTEVILLE (nih funded) |
| Locations | 1 site (FAYETTEVILLE, UNITED STATES) |
| Trial ID | NIH-10876032 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new therapeutic formulation that combines two growth factors, FGF1 and FGF2, to enhance the healing of chronic wounds, particularly in patients with diabetes and cardiovascular diseases. The approach aims to overcome common challenges in wound care, such as the instability of growth factors and the difficulty in delivering them effectively to the wound site. By creating a hyperstable version of these growth factors, the research seeks to improve healing outcomes and reduce the burden of chronic wounds on patients' quality of life. The effectiveness of this treatment will be monitored using advanced imaging techniques to ensure that it promotes healing effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from chronic wounds, particularly those with diabetes or cardiovascular conditions.
Not a fit: Patients with acute wounds or those not suffering from chronic conditions related to wound healing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the healing process for patients with chronic wounds, leading to better health outcomes and enhanced quality of life.
How similar studies have performed: Previous research has shown promise in using growth factors for wound healing, but this specific approach of creating a hyperstable formulation is novel.
Where this research is happening
FAYETTEVILLE, UNITED STATES
- UNIVERSITY OF ARKANSAS AT FAYETTEVILLE — FAYETTEVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THALLAPURANAM, SURESH KUMAR KRISHNASWAMY — UNIVERSITY OF ARKANSAS AT FAYETTEVILLE
- Study coordinator: THALLAPURANAM, SURESH KUMAR KRISHNASWAMY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.